Fully human single-domain antibodies represent a major technological breakthrough in therapeutic antibody engineering. Characterized by their ultra-compact nano-scale architecture, they exhibit enhanced tissue penetration capabilities, crossing challenging interfaces like the blood-brain barrier (BBB) to enable therapies across oncology and neurodegenerative diseases.
However, traditional VHH discovery heavily relies on camelid models, which necessitates complex, costly, and time-consuming downstream humanization processes to mitigate immunogenicity risks in human clinical applications. HUGO-Nano™ was engineered to decisively bridge the current developmental gap by uniting the immense structural versatility of single-domain antibodies with the profound clinical safety of fully human sequences. By generating fully human heavy-chain antibodies (HcAbs) directly from immunization—a true "zero humanization" process—the platform effectively shaves months off traditional R&D timelines. Furthermore, this direct in vivo approach substantially mitigates the risk of anti-drug antibody (ADA) responses while retaining exceptional antigen affinity and thermodynamic stability. Ultimately, HUGO-Nano™ significantly accelerates clinical translation and provides an optimal, highly scalable foundation for tackling complex disease targets.
The HUGO-Nano™ mouse is a genetically engineered in vivo model designed to directly generate fully human heavy-chain-only antibodies (HcAbs). Characterized by a single heavy-chain architecture, these unique molecules bind directly to target antigens without the need for a light chain, structurally mirroring the efficiency of traditional camelid single-domain antibodies.
-
1.Fully Human Germline Framework to Reduce Immunogenicity RiskCompared with conventional camelid-derived single-domain antibody systems, HUGO-Nano™ mice directly generate fully human-sequence single-domain antibody candidates without requiring multiple rounds of in vitro humanization. This may help reduce the potential risk of anti-drug antibody responses in humans while streamlining the preclinical antibody discovery workflow and lowering overall development costs.
-
2.Excellent Physicochemical Stability for Developable Single-Domain AntibodiesMolecules generated from the HUGO-Nano™ platform demonstrate strong thermal stability, with DSF-measured Tm values generally above 60°C. After 14 days of accelerated stability testing at 40°C, the main peak profiles remain well controlled by SEC, icIEF, and CE-SDS analysis, indicating favorable storage stability, process tolerance, and developability.
-
3.Modular Single-Domain Architecture for Multi-Format Antibody EngineeringThe natural single-domain structure can serve as a standardized molecular module for rapid tandem assembly through molecular engineering. This enables the construction of bispecific and multispecific antibodies, as well as next-generation antibody-drug conjugate formats, supporting multi-target recognition and flexible therapeutic antibody design.
-
4.Compact Molecular Size with Enhanced Tissue Penetration PotentialWith a smaller molecular size than full-length IgG antibodies, single-domain antibody molecules can access challenging epitopes such as deep antigen pockets and hidden clefts that are often difficult for conventional IgG antibodies to bind. Their compact structure may also support improved penetration across biological barriers and into solid tumor tissue, helping enhance target-site enrichment and therapeutic potential.
- {{v2}}
- {{item}}
- {{v2}}
- {{item}}
